From mice to men: GEMMs as trial patients for new NSCLC therapies

Sarah A. Hayes, Amanda L. Hudson, Stephen J. Clarke, Mark P. Molloy, Viive M. Howell*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    15 Citations (Scopus)

    Abstract

    Given the large socio-economic burden of cancer, there is an urgent need for in vivo animal cancer models that can provide a rationale for personalised therapeutic regimens that are translatable to the clinic. Recent developments in establishing mouse models that closely resemble human lung cancers involve the application of genetically engineered mouse models (GEMMs) for use in drug efficacy studies or to guide patient therapy. Here, we review recent applications of GEMMs in non-small cell lung cancer research for drug development and their potential in aiding biomarker discovery and understanding of biological mechanisms behind clinical outcomes and drug interactions.

    Original languageEnglish
    Pages (from-to)118-127
    Number of pages10
    JournalSeminars in Cell and Developmental Biology
    Volume27
    DOIs
    Publication statusPublished - Mar 2014

    Keywords

    • Mouse model
    • Lung cancer
    • Genetically engineered mouse model (GEMM)
    • EML4-ALK
    • Kras
    • EGFR

    Fingerprint

    Dive into the research topics of 'From mice to men: GEMMs as trial patients for new NSCLC therapies'. Together they form a unique fingerprint.

    Cite this